免疫表型异常的DLBCL病理及临床分析  

Pathological and clinical analysis of immunophenotypic abnormalities in DLBCL

作　　者：李璐 刘雨晴 张树鹏 丁宝琪 LI Lu;LIU Yuqing;ZHANG Shupeng;DING Baoqi(Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250117,China;Department of Pathology,The Second Affiliated Hospital of Shandong First Medical University,Taian 271000,China)

机构地区：[1]山东第一医科大学(山东省医学科学院),山东济南250117 [2]山东第一医科大学第二附属医院病理科,山东泰安271000

出　　处：《山东第一医科大学（山东省医学科学院）学报》2022年第2期90-95,共6页Journal of Shandong First Medical University ＆ Shandong Academy of Medical Sciences

摘　　要：目的探究CD5^(+)、CD21^(+)的弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)病理及临床特征。方法回顾性分析2015年1月1日至2017年12月31日山东第一医科大学第二附属医院诊治的62例DLBCL初发患者的临床病理资料,免疫组化检测CD5、CD21的表达,并根据CD5、CD21是否阳性表达、年龄、性别、病理分型、临床分期、累及部位、B症状(发热、乏力、消瘦和盗汗等全身症状)有无对患者进行分组,然后比较各组患者的生存情况。结果本研究62例DLBCL患者中,CD5阳性表达者9例(14.52%),CD21阳性表达者15例(24.19%)。CD5的表达与性别、临床分期、累及部位有关,与年龄、病理分型、B症状无关;CD21的表达与累及部位有关,与年龄、性别、临床分期、B症状及病理分型均无关。CD5阳性组无进展生存时间(progression-free survival,PFS)显著低于CD5阴性组;CD21阳性组PFS显著高于CD21阴性组。结论CD5表达阳性的DLBCL患者的预后较差;CD21表达阳性的DLBCL患者的预后较好。Objective:To explore the pathological and clinical characteristics of diffuse large B cell lymphoma(DLBCL)of CD5^(+)and CD21^(+).Methods:The clinicopathological data of 62 patients with initial onset of DLBCL from January 1,2015 to December 31,2020 in the Second Affiliated Hospital of Shandong First Medical University were retrospectively analyzed.The expressions of CD5 and CD21 were detected by immunohistochemistry.The patients were divided into groups according to whether or not CD5 and CD21 were expressed positively,age,sex,pathological type,clinical stage,site of involvement and with or without symptom B,and then the survival of patients in each group was compared.Results:Among the 62 DLBCL patients in this study,9 cases(14.52%)were CD5 positive and 15 cases(24.19%)were CD21 positive.The expression of CD5 was correlated with gender,age,clinical stage and symptom B,but not with pathological classification and involved site.The expression of CD21 was correlated with age,but not with gender,clinical stage,symptom B,site of involvement and pathological classification.PFS in CD5 positive group was significantly lower than that in CD5 negative group.PFS in CD21 positive group was significantly higher than that in CD21 negative group.Conclusion:The prognosis of DLBCL patients with CD5 positive expression is poorwhile the prognosis of DLBCL patients with CD21 positive expression is good.

关 键 词：弥漫大B细胞淋巴瘤 CD5 CD21 免疫表型异常 

分 类 号：R733.1[医药卫生—肿瘤]